GlobeNewsWire
04 Dec 2025, 21:01 UTC · 45w ago
Verdict
Headline takes no side. We score PRAX +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Praxis Precision Medicines successfully completed a pre-NDA meeting with the FDA and gained alignment on the content of the NDA for ulixacaltamide.
More positive than 99% of claims this week
Praxis expects to submit the NDA for ulixacaltamide in essential tremor in early 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 94% of claims this week
Ulixacaltamide demonstrated statistically significant and clinically meaningful improvements in daily functioning in the Essential3 program.
More positive than 90% of claims this week
Essential tremor represents a multi-billion-dollar commercial opportunity with millions of patients currently lacking effective and safe treatment options.
More positive than 80% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced a successful pre-NDA meeting with the FDA and alignment on the submission of its first New Drug Application in early 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
6h ago
+35.0%
Price agrees with the score
$256.47 vs $189.97 close before publication (Dec 4) · not market-adjusted
PRAX chart →
